Mergers & acquisitions
Following a partnership with Bit Bio announced earlier this month, this morning, CRL announced the acquisition of HemaCare for approximately $380 million in cash.
The Beacon optofluidic technology will be used to speed the identification of lifesaving treatments for deadly viruses including Ebola, Lassa and others.
Merck snapped up the company to gain ArQule’s lead investigational candidate, ARQ 531, a novel, oral Bruton’s tyrosine kinase inhibitor currently in a Phase II dose-expansion study for the treatment of B-cell malignancies.
Sanofi announced it is acquiring Synthorx for $68 per share in cash, a value of $2.5 billion. The deal has been unanimously approved by both companies’ boards.
The merger is an effort on the part of Astellas to strengthen its genetic medicine and gene therapy business.
€8 million acquisition brings a wide range of revenue-generating products in orthopaedic, spine, dental and sports surgery
Proteros biostructures GmbH announced that Rodin Therapeutics, Inc., a Boston, MA based biotech company developing novel, small molecule therapeutics for synaptopathies has been acquired by Alkermes plc, a global biopharmaceutical company headquartered in Dublin, Ireland.
BioNovelus, Inc. announces the closing of its previously announced acquisition of Corvus Consulting, LLC..
Patented AltuCaps® for Microencapsulation of stem cells for autoimmune and inflammatory diseases: Partnering opportunities available
Agreement provides Enochian with exclusive rights to develop and commercialize a HBV treatment with a novel mechanism of action
PRESS RELEASES